Losses extended over Chinese economic concerns

The markets continued falling during the midday with the Dow dropping 76 points to 17,202 over concerns that the Chinese economy was slowing. Nasdaq plunged 59 points to 4,520.

On the upside

The Food and Drug Administration has authorized Tekmira Pharmaceuticals (Nasdaq: TKMR) to provide TKM-Ebola to treat patients with confirmed or suspected Ebola infections.

NXT-ID (Nasdaq: NXTD) was uplisted to Nasdaq from Nasdaq Capital Market.

Clorox (NYSE: CLX) will close its operations in Venezuela and sell its assets.

On the downside

The Independent Data Monitoring Committee recommended that Threshold Pharmaceuticals' (Nasdaq: THLD) Phase 3 clinical trial of TH-302 in patients with advanced soft tissue sarcoma continue as planned.

TriMas (Nasdaq: TRS) cut its earnings outlook for the full year and announced plans to purchase Allfast Fastening Systems.

Shares of SinoCoking Coal and Coke Chemical Industries (Nasdaq: SCOK) extended its losses.

In the broad market, declining issues outpaced advancers by a margin of more than 5 to 1 on the NYSE and by more than 4 to 1 on Nasdaq. The broader S&P 500 fell 14 points to 1995. Bitcoin added $6 to $394.